Neuralgia Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The neuralgia treatment market size has grown strongly in recent years. It will grow from $2.3 billion in 2024 to $2.44 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to rising prevalence of neuralgia, neuropathic pain awareness, rise in chronic pain conditions, presence of high disposable income, government initiatives.

The neuralgia treatment market size is expected to see strong growth in the next few years. It will grow to $3.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to aging population, emerging therapies, increasing incidences of diabetes, high healthcare expenditure. Major trends in the forecast period include advancements in pain management, innovative products, digital health integration, development of new drug delivery systems.

The growing prevalence of chronic diseases, such as diabetes, is expected to drive the expansion of the neuralgia treatment market. Chronic diseases are long-term conditions that require ongoing medical care, limit daily activities, or both. Diabetes, a metabolic disorder marked by elevated blood glucose levels, is one such condition. Neuralgia treatments can help manage diabetic neuropathy, a type of nerve damage commonly seen in individuals with diabetes. For example, in September 2023, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that 41 million deaths, or 74% of those caused by non-communicable diseases (NCDs), occur globally each year. As a result, the increasing prevalence of chronic diseases, including diabetes, is fueling the growth of the neuralgia treatment market.

The expected rise in the number of surgical procedures is anticipated to drive the growth of the neuralgia treatment market. Surgical procedures involve medical interventions that either require incisions or utilize minimally invasive techniques to access and treat tissues or organs within the body. These procedures contribute to the expansion of the neuralgia treatment market by providing options for patients when non-surgical treatments are ineffective or when a specific anatomical issue can be surgically addressed. For example, in February 2024, the National Healthcare Statistics, a US-based government agency, reported that cataract surgery was the most commonly performed procedure in 2022, with 39,347 cases, 98.3% of which were day cases. This was followed by 20,537 caesarean sections and 12,830 hip replacements, most of which were inpatient procedures. Thus, the increasing number of surgical procedures is expected to drive the growth of the neuralgia treatment market.

Major players in the neuralgia treatment market are dedicated to the development of cutting-edge products and solutions to maintain their competitive edge in the industry. As an illustration, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Shingrix, the world's first non-live recombinant subunit vaccine. This vaccine is specifically designed to prevent shingles and post-herpetic neuralgia in adults aged 50 years and above, administered intramuscularly in two doses. Shingrix leverages the antigen glycoprotein E along with the adjuvant system AS01B to generate a potent and long-lasting immune response, countering age-related immune system deterioration. Clinical trials have demonstrated its remarkable 97% effectiveness in preventing shingles in adults, while also effectively guarding against post-herpetic neuralgia, a painful complication of shingles.

In November 2022, Kriya Therapeutics Inc., a gene therapy company based in the United States, completed the acquisition of Redpin Therapeutics Inc. The specific financial details of the transaction were not disclosed. This strategic acquisition is poised to enhance Kriya Therapeutics Inc.'s gene therapy portfolio for addressing neurological disorders, encompassing conditions like epilepsy, trigeminal neuralgia, and Parkinson's disease. Redpin Therapeutics Inc., also based in the United States, is a biotechnology company with a strong track record in effectively treating a range of neurological disorders, including neuralgia.

Major companies operating in the neuralgia treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Biogen Inc., Daiichi Sankyo Company Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Horizon Therapeutics, Purdue Pharma, Dr. Reddy's Laboratories, Cipla Limited, Hikma Pharmaceuticals PLC, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals, Glenmark Pharmaceuticals, Tonix Pharmaceuticals.

North America was the largest region in the neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuralgia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neuralgia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuralgia treatment market consists of revenues earned by entities by providing blood tests, magnetic resonance imaging (MRI), nerve conduction velocity tests, physical therapies and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuralgia treatment market also includes sales of anticonvulsant medications, pain relievers, antidepressants and antiseizure medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Neuralgia treatment involves addressing a medical condition characterized by persistent nerve-related pain, which can result from injury, infection, or underlying medical issues. This treatment aims to effectively manage symptoms, slow the progression of neuralgia, and prevent potential complications.

Neuralgia treatment primarily falls into two categories drug-based therapies and surgical interventions. Drug-based treatment involves the use of medications to manage, alleviate, or even cure various medical conditions and diseases, including diabetic neuropathy, intercostal neuralgia, occipital neuralgia, peripheral neuralgia, and postherpetic neuralgia. These medications are accessible through various distribution channels such as drug stores, hospital pharmacies, online pharmacies, and retail pharmacies. They are utilized in diverse healthcare settings, including hospitals, clinics, ambulatory surgery centers, and other medical facilities.

The neuralgia treatment market research report is one of a series of new reports that provides neuralgia treatment market statistics, including neuralgia treatment industry global market size, regional shares, competitors with a neuralgia treatment market share, detailed neuralgia treatment market segments, market trends and opportunities and any further data you may need to thrive in the neuralgia treatment industry. This neuralgia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.